A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Geographic Atrophy

In brief

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

Key facts

Study ID
NCT05019521
Run by
Alexion Pharmaceuticals, Inc.
People needed
365
Starts
2021-08-23
Expected to finish
2025-01-21
Last updated by the study team
2025-09-05

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.